Amylin reports weight-loss success with Symlin

San Diego-based Amylin has reported that a three-times-a-day injection of its diabetes drug Symlin -- a synthetic form of the human hormone amylin -- helped obese patients lose weight. The Phase II trial involving more than 200 patients led to a loss of 3.6 percent of the body weight of patients taking the hormone after 16 weeks of injections. Symlin was approved three months ago for type 1 and type 2 diabetes. Amylin tested the drug in people with a body mass index of 30 to 45 and found that the lightest group -- a BMI of 30 to 35 -- responded best in the study, losing 5 percent of their body weight. A new Phase II is under way to study another dosage.

- read this press release for more

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.